metaraminol has been researched along with Cardiac Hypertrophy in 1 studies
Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.
metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boldy, M | 1 |
| Ellestad, MH | 1 |
| Kemp, GL | 1 |
1 other study available for metaraminol and Cardiac Hypertrophy
| Article | Year |
|---|---|
The use of metaraminol in the evaluation of mitral insufficiency.
Topics: Adolescent; Adult; Aged; Blood Pressure; Capillaries; Cardiac Catheterization; Cardiomegaly; Cardiom | 1969 |